丹红联合腺苷钴胺治疗糖尿病周围神经病变100例疗效观察.doc

丹红联合腺苷钴胺治疗糖尿病周围神经病变100例疗效观察[摘要] 目的 观察丹红与腺苷钴胺联合应用治疗糖尿病周围神经病变的临床疗效。 方法 将100例糖尿病周围神经病变患者随机分为两组：观察组52例给予丹红联合腺苷钴胺治疗，对照组48例给予腺苷钴胺治疗，两组均进行常规治疗，治疗4周后进行临床疗效评定。 结果 治疗后观察组的临床总有效率为94.2%，对照组为75.0%，与观察组相比，差异有统计学意义（P 0.05）；观察组患者的正中神经、尺神经及胫神经的MCV和SCV均显著快于对照组患者，两组相比差异有统计学意义（P 0.05）。 结论 丹红联合腺苷钴胺治疗糖尿病周围神经病变疗效显著，优于单用腺苷钴胺。 [关键词] 丹红；腺苷钴胺；糖尿病周围神经病变 [中图分类号] R587.2 [文献标识码] B [文章编号] 1673—9701（2012）27—0077—03 Clinical observation of danhong combined with cobamamide in treating diabetic peripheral neuropathy DONG Haiping1 WU Zhongsheng2 1.First Department of Internal Medicine， Traditional Chinese Medicine Hospital of Yueqing， Yueqing 325600， China； 2.Department of Cardiology， Traditional Chinese Medicine Hospital of Yueqing， Yueqing 325600， China [Abstract] Objective To observe the therapeutic effects of danhong combined with cobamamide on diabetic peripheral neuropathy. Methods One hundred cases patients with diabetic peripheral neuropathy were randomly divided into the observation group and the control group， 52 cases and 48 cases， respectively. On the basis of conventional treatment，the patients of observation group were given with danhong combined with cobamamide， while the patients of control group were given with cobamamide alone. After 4 weeks，the therapeutic effects were evaluated. Results Clinical efficacy rate of observation group and control group was 94.2% and 75.0%， respectively （P 0.05）. Compared with that before the treatment，the clinical symptoms and physical signs of the observation group obviously ameliorated，MCV and SCV of the observation group increased significantly （P 0.05）. Conclusion The therapeutic effects of danhong combined with cobamamide on diabetic peripheral neuropathy surpass remarkably cobamamide used alone. [Key words] Danhong； Cobamamide； Diabetic peripheral neuropathy 糖尿病周围神经病变（diabetic peripheral neuropathy，DPN）是糖尿病最常见的慢性并发症之一，临床发病率高，是糖尿病患者致残的主要因素，严重影响糖尿病患者的健康和生活质量[1]。目前糖尿病周围神经病变的治疗是在控制患者血糖基础上进行的，同时给予营养神经治疗。腺苷钴胺属于神经营养药物，可加强神经细胞内核酸和蛋白质的合成